Insmed Incorporated (INSM)

Market Cap	3.73B
Revenue (ttm)	305.21M
Net Income (ttm)	-749.57M
Shares Out	148.49M
EPS (ttm)	-5.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,717
Open	25.44
Previous Close	25.81
Day's Range	24.81 - 25.44
52-Week Range	18.09 - 32.00
Beta	0.92
Analysts	Strong Buy
Price Target	45.58 (+81.78%)
Earnings Date	May 2, 2024

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 912
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM

Financial Performance

In 2023, Insmed's revenue was $305.21 million, an increase of 24.39% compared to the previous year's $245.36 million. Losses were -$749.57 million, 55.7% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $45.58, which is an increase of 81.78% from the latest price.

Price Target

$45.58

(81.78% upside)

Analyst Consensus: Strong Buy